A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

NCT06917742

Status	RECRUITING
Phase	Phase 1
Sponsor	Capstan Therapeutics
Enrollment	64 participants

Key Eligibility Criteria

Inclusion (9)

- Male and female participants who are healthy as determined by the investigator based on review of medical history, physical examination, and clinical laboratory tests obtained during the screening period.
- Participant is willing and able to adhere to the study visit schedule and other protocol requirements.
- RA Only:
- Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA
- Presence of rheumatoid factor or ACPA above the ULN

... and 4 more (see full listing online)

Exclusion (6)

- Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, or clinical laboratory tests beyond what is consistent with a healthy population in the region in which the study is conducted.
- Use of any investigational medical device or investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first administration of CPTX2309.
- RA Only:
- \- Participants diagnosed with Felty's syndrome
- SLE Only:

... and 1 more (see full listing online)

Locations (1 total)

Nucleus Network Brisbane, Herston, Queensland, Australia